MilliporeSigma, the life sciences division of Merck KGaA, has positioned itself for growth in the organoid development market through its €104 million ($120 million) acquisition of HUB Organoids completed last year. The company has also established a partnership with Promega to further strengthen its organoid capabilities.
Organoids are three-dimensional cell cultures that mimic the structure and function of human organs, making them valuable tools for drug discovery, disease modeling, and personalized medicine research. The technology has gained significant traction in pharmaceutical development as companies seek better preclinical models.